MA29212B1 - Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost') - Google Patents

Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost')

Info

Publication number
MA29212B1
MA29212B1 MA29903A MA29903A MA29212B1 MA 29212 B1 MA29212 B1 MA 29212B1 MA 29903 A MA29903 A MA 29903A MA 29903 A MA29903 A MA 29903A MA 29212 B1 MA29212 B1 MA 29212B1
Authority
MA
Morocco
Prior art keywords
primo
immunization
boost
prime
malaria vaccines
Prior art date
Application number
MA29903A
Other languages
English (en)
Inventor
Maria Grazia Pau
Jaap Goudsmit
Joseph D Cohen
Patrice M Dubois
Ann V Stewart
Donald Heppner
Original Assignee
Crucell Holland Bv
Us Gov Sec Army
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Us Gov Sec Army, Glaxosmithkline Biolog Sa filed Critical Crucell Holland Bv
Publication of MA29212B1 publication Critical patent/MA29212B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVELLES STRATÉGIES DE VACCINATION, DANS LESQUELLES DES STRATÉGIES DU TYPE PRIMO-IMMUNISATION/RAPPEL ('PRIME/BOOST') SPÉCIFIQUES SONT APPLIQUÉES À L'AIDE DE VECTEURS ADÉNOVIRAUX RECOMBINÉS FAIBLEMENT NEUTRALISÉS, QUI CONTIENNENT DES ACIDES NUCLÉIQUES CODANT POUR DES ANTIGÈNES DE PLASMODIUM FALCIPARUM; ET DES VACCINS À BASE DE PROTÉINES RECOMBINÉES PURIFIÉES TELLES QUE RTS,S, QUI COMPRENNENT DES ADJUVANTS APPROPRIÉS.
MA29903A 2004-10-14 2007-05-14 Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost') MA29212B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61905604P 2004-10-14 2004-10-14
EP04105035 2004-10-14

Publications (1)

Publication Number Publication Date
MA29212B1 true MA29212B1 (fr) 2008-02-01

Family

ID=34929701

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29903A MA29212B1 (fr) 2004-10-14 2007-05-14 Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost')

Country Status (24)

Country Link
US (3) US20080131461A1 (fr)
EP (1) EP1802336B1 (fr)
JP (1) JP5108521B2 (fr)
KR (1) KR20070104881A (fr)
CN (1) CN101068568B (fr)
AT (1) ATE523205T1 (fr)
AU (1) AU2005293572B2 (fr)
BR (1) BRPI0518146A (fr)
CA (1) CA2582455A1 (fr)
CY (1) CY1112749T1 (fr)
DK (1) DK1802336T3 (fr)
EA (1) EA016648B1 (fr)
ES (1) ES2371175T3 (fr)
HR (1) HRP20110786T1 (fr)
IL (2) IL182357A0 (fr)
MA (1) MA29212B1 (fr)
MX (1) MX2007004031A (fr)
NO (1) NO20072470L (fr)
NZ (1) NZ583291A (fr)
PL (1) PL1802336T3 (fr)
PT (1) PT1802336E (fr)
RS (1) RS52187B (fr)
SI (1) SI1802336T1 (fr)
WO (1) WO2006040334A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
JP4480398B2 (ja) * 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
WO2004055187A1 (fr) 2002-12-17 2004-07-01 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ES2371175T3 (es) * 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008288508B2 (en) 2007-08-13 2014-05-01 Glaxosmithkline Biologicals S.A. Vaccines
PT2220242T (pt) 2007-11-28 2017-04-03 Univ Pennsylvania Adenovírus símio da subfamília b sadv-28,27,-29,-32,-33 e -35 e suas utilizações
KR101761691B1 (ko) 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
CA2707245A1 (fr) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccin
EP2250255A2 (fr) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Adénovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
EP2346523A4 (fr) * 2008-10-01 2014-12-31 Us Health Vaccin multicomposant contre la malaria induisant des réponses immunitaires durables contre le plasmodium
WO2010060719A1 (fr) 2008-11-03 2010-06-03 Crucell Holland B.V. Procédé pour la production de vecteurs adénoviraux
AU2010272685B2 (en) 2009-07-16 2015-02-26 Crucell Holland B.V. Production of polio virus at high titers for vaccine production
MX354752B (es) * 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
PL2655604T3 (pl) * 2010-12-14 2019-02-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom
AU2012243039B2 (en) * 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
NZ717682A (en) 2012-02-16 2017-10-27 Vlp Therapeutics Llc Virus like particle composition
SG10201609511XA (en) 2012-05-18 2016-12-29 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
CN105431535A (zh) * 2013-06-03 2016-03-23 Vlp治疗有限责任公司 疟疾疫苗
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
NZ727020A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
WO2016059911A1 (fr) * 2014-10-17 2016-04-21 国立大学法人金沢大学 Vaccin antipaludéen
US20210260176A1 (en) * 2017-03-30 2021-08-26 United States Of America As Represented By The Secretary Of The Navy Methods and Compositions for Vaccinating Against Malaria
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
CA3091969A1 (fr) * 2018-02-22 2019-08-29 Turnstone Limited Partnership Virus oncolytiques en tant qu'adjuvants
CN113453707A (zh) * 2018-12-21 2021-09-28 库瑞瓦格股份公司 用于疟疾疫苗的rna
CN113966228A (zh) * 2019-06-11 2022-01-21 葛兰素史密斯克莱生物公司 黏膜疫苗配制剂
KR20220160042A (ko) 2020-03-27 2022-12-05 스벤스카 박신파브리셴 프로둑숀 아베 코로나바이러스의 치료 및 예방을 위한 조성물 및 방법
EP4135847A4 (fr) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Vaccin contre un coronavirus
WO2021221127A1 (fr) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Immunothérapie à cytokine
WO2023056284A1 (fr) 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions et méthodes de traitement et de prévention d'infections à coronavirus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
CA2123612C (fr) * 1991-11-16 2002-06-25 Michel De Wilde Proteine hybride entre la proteine cs de plasmodium et l'antigene de surface du virus de l'hepatite b
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
JP4480398B2 (ja) * 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
WO2004037294A2 (fr) * 2002-10-23 2004-05-06 Crucell Holland B.V. Nouveaux parametres pour vaccins a base d'adenoviraux recombinants
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
WO2004055187A1 (fr) * 2002-12-17 2004-07-01 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ES2371175T3 (es) * 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
KR101255861B1 (ko) * 2004-11-11 2013-04-17 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 조성물 및 그것의 용도

Also Published As

Publication number Publication date
CN101068568A (zh) 2007-11-07
IL182357A0 (en) 2007-07-24
AU2005293572B2 (en) 2011-08-04
NZ583291A (en) 2011-06-30
SI1802336T1 (sl) 2012-01-31
US20080131461A1 (en) 2008-06-05
US20120014994A1 (en) 2012-01-19
EA016648B1 (ru) 2012-06-29
IL214460A0 (en) 2011-09-27
AU2005293572A1 (en) 2006-04-20
DK1802336T3 (da) 2011-11-14
US20090285879A1 (en) 2009-11-19
EP1802336B1 (fr) 2011-09-07
RS52187B (sr) 2012-10-31
HRP20110786T1 (hr) 2011-12-31
NO20072470L (no) 2007-07-16
WO2006040334A1 (fr) 2006-04-20
HK1100121A1 (en) 2007-09-07
PT1802336E (pt) 2011-11-15
ATE523205T1 (de) 2011-09-15
EP1802336A1 (fr) 2007-07-04
CY1112749T1 (el) 2016-02-10
JP5108521B2 (ja) 2012-12-26
EA200700849A1 (ru) 2007-10-26
PL1802336T3 (pl) 2012-03-30
CA2582455A1 (fr) 2006-04-20
KR20070104881A (ko) 2007-10-29
CN101068568B (zh) 2012-09-26
BRPI0518146A (pt) 2008-10-28
MX2007004031A (es) 2007-11-08
JP2008516926A (ja) 2008-05-22
ES2371175T3 (es) 2011-12-28

Similar Documents

Publication Publication Date Title
ATE523205T1 (de) Prime-boost-impfstoffe gegen malaria
EP1490483A4 (fr) Incorporation in vivo d'acides amines non naturels
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
WO2006081007A3 (fr) Utilisation de flagelline en immunotherapie antitumorale
IL205958A0 (en) Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
WO2005007673A3 (fr) Peptides immunogenes
WO2003002065A3 (fr) Compositions de vaccin vhc e1e2
EP1575529A4 (fr) Peptides et procedes de criblage de vaccins a base de peptides immunogenes contre la maladie d'alzheimer
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
GB0113798D0 (en) Antigens and vectors for vaccination
WO2004053086A3 (fr) Antigenes de plasmodium falciparum et procedes d'utilisation
GB0118532D0 (en) Materials and methods relating to improved vaccination strategies
DK1845164T3 (da) Promoterer til ekspression i modificeret vacciniavirus ankara
BR0210252A (pt) Peptìdeos biologicamente ativos
MXPA03008832A (es) Vacunas contra leishmania.
WO2005014654A3 (fr) Complexes multimeres d'antigenes et d'un adjuvant
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
EP1667634A4 (fr) Vaccin contre l'anthrax
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2002092628A3 (fr) Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
WO2006110915A3 (fr) Formulations de vaccins pour leishmania
WO2001092496A3 (fr) Proteines kinases humaines isolees, molecules d'acide nucleique codant pour ces proteines kinases humaines et utilisations de celles-ci
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
WO2006126030A3 (fr) Vaccins contre la malaria